Response to crizotinib in ROS1-rearranged non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 27, 2012, Pages 3425-3426

  Komiya, Takefumi ^a   Thomas, Anish ^a   Khozin, Sean ^a   Rajan, Arun ^a   Wang, Yisong ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; PROTEIN; ROS1 PROTEIN; SCATTER FACTOR RECEPTOR; TYROSINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; IN VITRO STUDY; LETTER; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 84866749575     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.4556     Document Type: Letter

References (5)

1. Bergethon K, Shaw AT, Ou SH, et al: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870, 2012
2. Rikova K, Guo A, Zeng Q, et al: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203, 2007 (Pubitemid 350235027)
3. Tanizaki J, Okamoto I, Okamoto K, et al: MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 6:1624-1631, 2011
4. Blanco R, Iwakawa R, Tang M, et al: A gene-alteration profile of human lung cancer cell lines. Hum Mutat 30:1199-1206, 2009
5. Ou SH, Kwak EL, Siwak-Tapp C, et al: Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6:942-946, 2011